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C2238 ANP gene variant promotes 
increased platelet aggregation 
through the activation of Nox2 and 
the reduction of cAMP
Roberto Carnevale1, Pasquale Pignatelli2, Giacomo Frati1,3, Cristina Nocella1,2, Rosita 
Stanzione3, Daniele Pastori2, Simona Marchitti3, Valentina Valenti4, Maria Santulli5, 
Emanuele Barbato6,7, Teresa Strisciuglio7, Leonardo Schirone1, Carmine Vecchione3,8, 
Francesco Violi2, Massimo Volpe  3,9, Speranza Rubattu3,9 & Sebastiano Sciarretta1,3
Subjects carrying the C2238 variant of the atrial natriuretic peptide (ANP) gene have a higher occurrence 
of stroke and acute coronary syndrome, suggesting an increased predisposition to acute thrombotic 
events in these subjects. We evaluated for the first time the direct effects of mutant ANP (C2238/
αANP) on platelet activation in vitro and in human subjects. In vitro, platelets were incubated with no 
peptide, with T2238/αANP (WT) or with C2238/αANP at different concentrations. C2238/αANP (10−10 
M) induced higher collagen-induced platelet aggregation with respect to both control without ANP 
and T2238/αANP. This effect was even stronger at a higher concentration (10−6 M). Mechanistically, 
C2238/αANP significantly lowered platelet cAMP levels, increased ROS production and activated Nox2, 
with respect to both control and T2238/αANP. Forskolin, a cAMP activator, and sNOX2-tat, a Nox2 
inhibitor, significantly reduced the pro-aggregant effects of C2238/αANP. In vivo, we found that platelet 
aggregation resulted to be higher in patients with atrial fibrillation carrying the C2238 ANP gene variant 
with respect to non-carriers. In conclusions, C2238/αANP promotes platelet aggregation through the 
activation of Nox2 and the reduction of cAMP.
Atrial natriuretic peptide (ANP) is a cardiac hormone which belongs to the family of natriuretic peptides. It is 
mainly secreted by atria in response to hypervolemia, cardiac dysfunction or cardiac hypertrophy, thereby elicit-
ing diuretic, natriuretic and vasodilatory effects1. ANP also plays an important role in pleiotropic cardiovascular 
functions. It limits the development of cardiac hypertrophy and fibrosis and promotes endothelial cell survival 
and regenerative capacities1. However, accumulating lines of evidence demonstrated that the C2238 molecular 
variant of ANP (C2238/αANP) exerts detrimental vascular effects, predisposing to the development of cardio-
vascular diseases1. C2238/αANP is secondary to the T > C substitution at position 2238 of the ANP gene. Several 
studies demonstrated that subjects carrying the C2238 ANP gene variant have a higher risk of suffering a cardio-
vascular event2–8. We previously found that these subjects have a higher occurrence of stroke and acute coronary 
syndrome2, 5, 6. A previous study from Burnett’s group also showed that in an adult cohort from Olmsted County, 
which was followed up for 9 years, the C2238 ANP gene variant was associated with an increased incidence of 
cerebrovascular accidents and a higher prevalence of myocardial infarction4. In addition, previous work from 
Arnett’s group revealed a pharmacogenetic association of this ANP gene variant with cardiovascular disease 
1Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100, Latina (LT), 
Italy. 2Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, 00161, Rome (RM), 
Italy. 3Department of AngioCardioNeurology, IRCCS Neuromed, 86077, Pozzilli (IS), Italy. 4Department of Imaging, 
Bambino Gesù Children Hospital, IRCCS, Rome, Italy. 5Department of Experimental Medicine, Sapienza University 
of Rome, Rome, Italy. 6Cardiovascular Center Aalst, Onze-Lieve-Vrouw Hospital, Aalst, Belgium. 7Division of 
Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. 8University 
of Salerno, Medicine and Surgery, Baronissi (Salerno), Italy. 9Department of Clinical and Molecular Medicine, 
Sapienza University of Rome, Rome, Italy. Roberto Carnevale, Pasquale Pignatelli, Speranza Rubattu and Sebastiano 
Sciarretta contributed equally to this work. Correspondence and requests for materials should be addressed to S.R. 
(email: rubattu.speranza@neuromed.it) or S.S. (email: sebastiano.sciarretta@uniroma1.it)
Received: 10 November 2016
Accepted: 3 May 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 3797  | DOI:10.1038/s41598-017-03679-9
outcomes in hypertensive subjects from the ALLHAT study7. Of note, the clinical impact of this ANP gene variant 
appears to be highly relevant, since its prevalence in the general population ranges from 15 to 23%. A specific 
therapeutic strategy to reduce the incidence of adverse cardiovascular events in subjects carrying the C2238 ANP 
gene variant is not available yet.
Experimental studies from our group demonstrated that C2238/αANP reduces survival and functional capac-
ities of endothelial cells and vascular smooth muscle cells in vitro, through a deregulated activation of Type-C 
natriuretic peptide receptor (NPR-C)9, 10. This data indicates that C2238/αANP may predispose to the devel-
opment of cardiovascular diseases by directly damaging vascular cells. However, we previously found that in 
patients with stable coronary artery disease, the presence of C2238 ANP gene allele is associated with a higher 
incidence of acute coronary syndromes, without influencing the extent and severity of coronary atherosclerotic 
plaques5. This data suggests that C2238 ANP minor allele might either increase atherosclerotic plaque rupture or 
alternatively, predispose to thrombosis by directly increasing platelet aggregation. However, the effects of C2238/
αANP on platelet activity were never investigated.
Thus, the aim of our study was to evaluate the effects of C2238/αANP on platelet activation and aggregation in 
vitro and in patients with atrial fibrillation, a condition associated with thromboembolic events.
Results
In order to evaluate the effects of C2238/αANP on platelet activity, we incubated different concentrations of 
the peptide with human platelets from healthy subjects in vitro and then we measured platelet aggregation in 
response to a subthreshold concentration of collagen. We found that physiological (10−10 M) concentrations of 
C2238/αANP significantly induced platelet aggregation with respect to both control without ANP and T2238/
αANP (Fig. 1A). This effect was even stronger at a higher ANP concentration (10−6 M), thus demonstrating 
that C2238/αANP induces platelet aggregation. Different concentrations of C2238/αANP also induced a higher 
release of soluble CD40 ligand, as compared to both control without ANP and T2238/αANP (Fig. 1B). This data 
further indicates that C2238/αANP significantly induces platelet activation. We found that T2238/αANP also 
modestly stimulates platelet aggregation, particularly at high concentration.
Figure 1. C2238/αANP induces platelet activation. (A,B) Platelets were incubated without the peptide or 
with either T2238/αANP or C2238/αANP at the specified concentration (10−6 M or 10−10 M) and the platelet 
activation was triggered by a sub-threshold concentration of collagen (0.3 µg/ml). Platelet aggregation (A) and 
the concentration of the soluble CD40 ligand released by platelets (B) were assessed. N = 12. The results were 
expressed as mean ± SEM. In all the groups, a similar volume of solvent was added.
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Then, we evaluated the mechanisms through which C2238/αANP induces platelet activation and aggrega-
tion. We previously demonstrated that C2238/αANP binds to NPR-C with a high affinity and activates it in a 
deregulated manner. On the other hand, it modulates NPR-A similarly to T2238/αANP9. NPR-C is coupled to a 
Gαi protein, which inhibits adenylate cyclase and reduces intracellular cyclic AMP (cAMP) levels when NPR-C 
is activated11. Therefore, we tested the effects of different concentrations of C2238/αANP on intracellular levels 
of cAMP. We found that C2238/αANP significantly reduces intracellular levels of cAMP with respect to control 
without ANP and T2238/αANP (Fig. 2A). These effects were reversed by forskolin, an activator of adenylate 
cyclase.
Our previous work also showed that C2238/αANP induces ROS accumulation and Nox2 activation in 
endothelial cells through the reduction of cAMP9. Therefore, we tested the effects of C2238/αANP on hydro-
gen peroxide and Nox2 activation in platelets. We found that C2238/αANP increases hydrogen peroxide release 
from platelets and activates Nox2, as indicated by higher release of its cleavage product, a marker of activation 
(Fig. 2B,C). This data indicates that C2238/αANP induces oxidative stress and Nox2 activation in platelets.
In order to test the hypothesis that a deregulated activation of NPR-C by C2238/αANP mediates its 
pro-aggregant effects on platelets, we evaluated whether C-ANF4–23, a selective NPR-C agonist, mimics the effects 
of C2238/αANP on platelet aggregation. First of all, we found that NPR-C is well expressed in human platelets 
Figure 2. C2238/αANP reduces cAMP levels and promotes platelet oxidative stress. (A–C) Platelets were 
incubated without the peptide or with either T2238/αANP or C2238/αANP at the specified concentration 
(10−6 M or 10−10 M). Forskolin (10 µM) was also used where specified. After incubation and platelet stimulation 
with a sub-threshold concentration of collagen (0.3 µg/ml), intracellular cAMP levels (A), platelet hydrogen 
peroxide production (B) and platelet Nox2 activation (C) were assessed. N = 12. The results were expressed as 
mean ± SEM. In all the groups, a similar volume of solvent was added.
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(Supplementary Fig. S1). Interestingly, we found that platelet expression of NPR-C is higher in patients with a his-
tory of cardiovascular diseases and atrial fibrillation with respect to healthy subjects, thus indicating that NPR-C 
expression in platelets is directly correlated with cardiovascular risk status. Remarkably, we found that both phys-
iological (10−10 M) and high concentrations (10−6 M) of C-ANF4–23 significantly induce platelet aggregation and 
CD40L expression with respect to both control without ANP and T2238/αANP (Supplementary Fig. S2), thus 
demonstrating that a selective activation of NPR-C is sufficient to induce platelet aggregation and activation. 
C-ANF4-23 also increased hydrogen peroxide production and Nox2 activation, with respect to both control with-
out ANP and T2238/αANP (Supplementary Fig. S2).
Then, we investigated whether lower intracellular levels of cAMP and higher ROS production and Nox2 
activity are responsible for the increased platelet aggregation and activation induced by C2238/αANP. In fact, 
it is known that low intracellular levels of cAMP strongly induce platelet activation and aggregation12. Similarly, 
previous work demonstrated that Nox2 activation and high levels of ROS induce platelet aggregation13–16. We 
found that forskolin inhibited C2238/αANP-induced platelet aggregation and release of soluble CD40 ligand 
(Fig. 3A,B). In addition, forskolin inhibited C2238/αANP-induced hydrogen peroxide production and Nox2 
activation in platelets (Fig. 3C,D). Similarly, Nox2 inhibition significantly blunted C2238/αANP-induced 
platelet activation and hydrogen peroxide production (Fig. 3A–C). sNox2-tat also efficiently reduced C2238/
Figure 3. C2238/αANP induces platelet aggregation and oxidative stress by the inhibition of cAMP levels and 
activation of Nox2. (A–D) Platelets were incubated without the peptide or with C2238/αANP at the specified 
concentration (10−6 M or 10−10 M). Forskolin (10 µM) or sNOX2-tat (50 µM) were also used where specified. 
After incubation and platelet stimulation with a sub-threshold concentration of collagen (0.3 µg/ml), platelet 
aggregation (A), soluble CD40 ligand release (B), platelet hydrogen peroxide levels (C) and platelet Nox2 
activity were assessed. N = 12. The results were expressed as mean ± SEM. In all the groups, a similar volume of 
solvent was added.
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αANP-induced Nox2 activation (Fig. 3D). Overall, this data indicated that C2238/αANP induces platelet acti-
vation and aggregation through the reduction of intracellular cAMP levels and activation of Nox2. On the other 
hand, the effects of forskolin and sNOX2-tat on platelet aggregation induced by control and T2238/αANP were 
modest, consistently with the fact that cAMP and Nox2 are minimally modulated by these stimuli (Supplemental 
Fig. S3).
Finally, we wanted to extend this in vitro data to the clinical setting and tested whether subjects carrying 
the C2238 ANP gene variant display increased platelet aggregation. We enrolled a cohort of 195 patients with 
atrial fibrillation, a condition associated with high thromboembolic risk. Among these patients, 44 (39 heterozy-
gous, 5 homozygous) were carriers of the C2238 minor allele. Main clinical characteristics did not differ signif-
icantly between carriers and non-carriers (Table 1). Serum levels of NT-proANP were lower in carrier subjects 
with respect to non-carriers, with a difference that was marginally significant (Table 1). On the other hand, no 
differences were observed regarding C-reactive protein levels (Table 1). Platelet count appeared to be similar 
in non-carrier and carrier subjects (non-carriers, 217.3 ± 58.6 SD × 109/L vs. carriers, 204.4 ± 68.9 SD × 109/L; 
p = 0.316). Nonetheless, we found that carriers of the C2238 variant displayed higher platelet aggregation with 
respect to non-carriers (Fig. 4A). They also showed higher release of CD40 ligand (Fig. 4B). Interestingly, we 
found that subjects carrying the C2238 variant also demonstrated higher hydrogen peroxide release and Nox2 
activation in platelets (Fig. 4C,D), confirming that C2238/αANP induces ROS production and Nox2 activation in 
platelets in vivo. Of note, the highest rate of platelet aggregation and activation was observed in homozygous sub-
jects, confirming the existence of a dose-dependent effect of C2238/αANP on platelet function (Supplementary 
Fig. S4).
Discussion
In the present study, we explored the effects of a common ANP molecular variant on platelet aggregation and acti-
vation both in vitro and in a human cohort of patients with atrial fibrillation. We found that C2238/ αANP favors 
platelet aggregation and promotes ROS production in platelets through the reduction of intracellular cAMP lev-
els and the activation of Nox2 in vitro. Importantly, we found that patients with atrial fibrillation carrying the 
C2238 ANP gene variant had increased platelet aggregation, activation and ROS production when compared to 
non-carriers.
The C2238 ANP gene variant consists of a mutation within the stop codon in exon 3, which leads to the addi-
tion of two arginine residues to the C-terminal portion of the mature form of ANP1. In recent years, the C2238 
variant has emerged as a significant cardiovascular risk factor. In fact, subjects carrying the C2238 minor allele 
are at an increased risk for having a cerebrovascular accident or developing coronary artery disease2–8. In addi-
tion, human carriers also display early signs of endothelial dysfunction9. C2238/αANP directly induces vascular 
damage. In fact, we found that C2238/αANP induces apoptosis and oxidative stress in endothelial cells in vitro 
and reduces their angiogenetic properties. It also directly promotes endothelial dysfunction ex vivo9. In addition, 
C2238/αANP induces vascular smooth muscle cell death, migration and increased contraction, which represent 
typical phenotypic changes occurring during the process of vascular remodeling10, 17. Mechanistically, all of these 
Variables All (n = 195)
Non-carriers 
(n = 151) Carriers (n = 44) p
Age (years) 72.9 ± 9.6 73.4 ± 9.1 71.0 ± 10.9 0.143
Women (%) 38.5 35.8 47.7 0.163
CHA2DS2 VASc score 2.4 ± 1.5 2.5 ± 1.5 2.3 ± 1.5 0.444
Paroxysmal AF (%) 32.3 31.1 36.4 0.583
Time in therapeutic range (%) 61.4 ± 19.6 61.7 ± 19.0 60.3 ± 21.3 0.669
Arterial Hypertension (%) 86.2 85.4 88.6 0.804
Diabetes mellitus (%) 17.9 16.6 22.7 0.374
Heart failure (%) 14.4 12.6 20.5 0.222
History of ischemic stroke/
TIA (%) 17.7 18.8 14.0 0.650
History of cardiac events (%) 19.3 19.5 18.6 0.900
Ejection fraction (%) 54.6 ± 8.4 54.9 ± 7.9 53.4 ± 10.3 0.378
Left atrium diameter (mm) 44.3 ± 6.0 44.3 ± 5.9 44.1 ± 6.2 0.889
C-reactive protein (mg/dl) 0.22 [0.13–0.41] 0.22 [0.12–0.40] 0.23 [0.15–0.50] 0.567
NT-proANP (pg/ml) 57.5 [50.7–85.4] 61.7 [51.0–89.3] 52.3 [48.1–70.0] 0.040
Antiplatelet therapy (%) 9.2 10.6 4.5 0.373
Diuretics (%) 41.0 41.1 40.9 0.986
Statins (%) 31.3 31.1 31.8 0.931
RAS inhibitors (%) 60.5 58.9 65.9 0.484
Table 1. Baseline characteristics of the patients. Continuous data are expressed as mean ± SD or as median with 
interquartile ranges (CRP and NT-proANP). RAS: Renin-Angiotensin System; TIA: transient ischemic attack; 
AF: atrial fibrillation.
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changes occur secondary to deregulated activation of NPR-C. In fact, NPR-C inhibition consistently attenuated 
the detrimental effects of C2238/αANP.
In the current work, we significantly extended these previous observations by demonstrating that C2238/
αANP is also able to elicit direct pro-thrombotic effects on platelets by markedly increasing their aggregation and 
release of CD40 ligand. C2238/αANP also induced platelet oxidative stress. Of note, we also observed a proag-
gregant effect of wild type ANP at high concentrations, in accordance with a previous study by Loeb and Gear18 
demonstrating that high levels of ANP are significantly associated with increased cardiovascular events19, 20. 
However, other investigations showed that wild type ANP may not affect platelet aggregation or it may even 
reduce it in some cases21, 22. The apparent divergence may be easily explained by differences in the experimen-
tal procedures among the studies, particularly regarding the platelet incubation time with the peptide and the 
method used to trigger platelet aggregation.
We found that C2238/αANP induces platelet aggregation by reducing cAMP levels. In fact, the restoration 
of cAMP levels by forskolin inhibited the pro-aggregant effects of the mutant peptide. Intracellular cAMP is 
universally recognized as a critical regulator of platelet aggregation12. High cAMP levels strongly inhibit platelet 
aggregation whereas reduced cAMP levels increase it. Of note, a reduction of platelet intracellular cAMP levels 
represents the mechanism mediating the pro-aggregant effects of several platelet agonists, particularly ADP23, 24. 
The inhibitory effects of cAMP appear to be mediated by PKA, which inhibits platelet activity at multiple levels 
keeping platelets in a resting state.
We believe that C2238/αANP inhibits cAMP levels by strongly activating NPR-C. NPR-C appears to be the 
most abundant natriuretic peptide receptor in platelets25, 26. NPR-C is coupled to a Gαi protein, which inhibits 
Figure 4. C2238 ANP gene variant is associated with increased platelet aggregation and oxidative stress. (A–D) 
Platelet aggregation (A), soluble CD40 ligand release (B), platelet hydrogen peroxide levels (C) and platelet 
Nox2 activity were assessed in subjects not carrying the variant and in subjects carrying the C2238 ANP gene 
variant. The results were expressed as mean ± SEM.
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adenylate cyclase and cAMP production when the receptor is activated, thereby lowering intracellular cAMP 
levels. We previously observed that C2238/αANP binds to NPR-C with a higher affinity than wild type ANP and 
it activates this receptor in an exaggerated manner9. NPR-C knockdown rescues cAMP levels in endothelial cells 
incubated with C2238/αANP9. Therefore, it is very likely that C2238/αANP lowers platelet cAMP levels through 
the activation of NPR-C. Unfortunately, an inhibitor of NPR-C is not commercially available and it is not possible 
to knockdown NPR-C in platelets and then test aggregation. Therefore, the only feasible way to dissect the specific 
role of NPR-C in the regulation of platelet reactivity was to test the effects of its agonist. We found that C-ANF4–23, 
a selective NPR-C agonist, mimics the effects of C2238/αANP on platelet aggregation. This data is consistent with 
the evidence that ADP, a strong platelet agonist, reduces intracellular cAMP levels and induces platelet aggrega-
tion by activating the P2Y2 receptor23, 24, which is also coupled to a Gαi protein.
Of note, we found that platelet NPR-C expression level is higher in subjects with a history of cardiovascular 
diseases and atrial fibrillation with respect to healthy subjects, thereby suggesting that subjects at high cardiovas-
cular risk are in general more vulnerable to the effects of C2238/αANP. Future studies are warranted to investigate 
whether an increased platelet expression of NPR-C in subjects at high cardiovascular risk contribute to the higher 
platelet reactivity and higher incidence of acute cardiovascular events observed in these subjects.
The proaggregant effects of C2238/αANP appears to also be mediated by Nox2 activation13–16. Nox2 is a major 
NADPH oxidase isoform in the cardiovascular system27. Nox2 is activated in response to stress thereby promoting 
ROS production and cardiovascular damage27. Our previous work demonstrated that Nox2 is also abundant in 
platelets, in which it regulates aggregation13–16. Nox2 was shown to be activated in platelets by cardiovascular risk 
factors, such as diabetes and dyslipidemia, thereby promoting superoxide generation and platelet aggregation. 
On the other hand, Nox2 inhibition was shown to reduce platelet aggregation14. ROS appear to activate platelets 
through calcium mobilization, reduction of nitric oxide levels and isoprostane production. In our study, we found 
that C2238/αANP promotes platelet activation of Nox2 in vitro. In addition, platelets from subjects carrying the 
C2238 ANP gene variant also displayed an increased Nox2 activation and ROS levels. Importantly, we found that 
pharmacological Nox2 inhibition significantly reduces platelet aggregation induced by C2238/αANP. This result 
is consistent with our previous data in endothelial cells, in which we observed that C2238/αANP induces ROS 
production and Nox2 activation9 and that NADPH oxidase inhibition partially rescues the detrimental effects of 
the mutant peptide9. Of note, forskolin inhibited C2238/αANP-induced ROS production and Nox2 activation in 
platelets. This evidence indicates that reduced levels of cAMP in response to C2238/αANP exposure contribute 
to Nox2 activation. This data is also consistent with previous results demonstrating that reduced cAMP levels 
promote NADPH oxidase activation9, 11, 28, 29.
We believe that our work has several clinical implications. Currently, there is no specific treatment able to 
reduce the increased cardiovascular risk of subjects carrying the C2238 ANP gene variant. Nox2 and ROS pro-
duction might represent a potential therapeutic target. Nox2 inhibition would also reduce vascular oxidative 
stress and dysfunction induced by C2238/αANP. It should be pointed out that Nox2 inhibition should be partial 
and not complete, so that the systemic physiological functions exerted by Nox2 can still be preserved.
In addition, it is known that subjects with atrial fibrillation are prone to suffer from thromboembolism and 
cardiovascular events30. Previous work demonstrated that atrial fibrillation is associated with enhanced plate-
let activity, conferring a high risk of major adverse cardiovascular events31. In addition, Nox2-dependent ROS 
production was found to be associated with atherosclerotic ischemic complications in the setting of atrial fibril-
lation32. We think that medical attention should be devoted to subjects affected by atrial fibrillation carrying the 
C2238 gene variant since they may have an increased risk to incur thromboembolic events. It is possible that 
carriers affected by atrial fibrillation may benefit also from a therapy with platelet aggregation inhibitors, although 
this hypothesis needs to be tested in future studies.
Finally, future studies are needed to study the impact of C2238 variant on platelet aggregation in subjects with 
coronary artery disease, particularly those under treatment with antiplatelet drugs. In fact, the level of platelet 
inhibition reached by standard antiplatelet drug therapy may not be sufficient in subjects carrying the C2238 
minor allele.
Our study demonstrated that C2238/αANP is associated with an increased platelet activation through the 
stimulation of Nox2 and the reduction of cAMP. These data suggest that C2238/αANP may induce the develop-
ment of cardiovascular diseases not only inducing vascular damage and favoring atherosclerotic plaque rupture, 
but also by directly increasing platelet aggregation and inducing atherothrombotic events. We believe that Nox2 
inhibition might represent a potential therapeutic intervention to reduce the cardiovascular risk in subjects car-
rying the C2238 ANP gene variant.
Methods
Platelet Aggregation Studies. In order to obtain platelet-rich plasma (PRP), citrated blood samples were 
centrifuged for 15 minutes at 180 g. To avoid leukocyte contamination, only the top 75% of the PRP was collected 
according to Pignatelli et al.14.
For the in vitro study, PRP samples from healthy subjects were pre-incubated (30 minutes at 37 °C) with differ-
ent ANP peptides and inhibitors. In order to investigate the mechanisms of C2238/αANP-induced platelet acti-
vation, we used forskolin (10 µM), which actives adenylate cyclase, sNOX2-tat (AnaSpec, 50 µM), which inhibits 
NADPH oxidase activation and C-ANF4–23, a selective agonist of NPR-C (10−10 and 10−6 M). Synthetic wild type 
αANP (T2238/αANP) and mutant αANP (C2238/αANP) were purchased from Primm (codes 201409-00026 
and 201409-00027 for C2238/αANP and T2238/αANP, respectively) and used at different concentrations which 
were achieved by diluting the peptide in water (10−10 and 10−6 M). In the control groups not treated with ANP 
peptides, the same volume of water was always added, as a control. Platelet number was the same for all the 
experimental groups and aggregation was induced by a sub-threshold concentration (STC) of collagen (Mascia 
Brunelli, 0.3 µg/mL in water) for 10 minutes. Platelet aggregation was measured as previously described33 with a 
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Light Transmission Aggregometry (Cronolog) and the STC concentration of agonists was defined as the highest 
concentration that elicited <15% platelet aggregation. After activation, samples were centrifuged for 3 minutes 
at 3000 g.
Citrated blood and PRP samples were obtained from healthy subjects without cardiovascular diseases, who 
were enrolled in Policlinico Umberto I – Sapienza University of Rome, Italy, according to guidelines and regula-
tions. The study protocol was approved by the local ethical board of Sapienza University of Rome and was con-
ducted according to guidelines and regulations. Informed consent was obtained from all subjects.
For the in vivo study, platelets were obtained from subjects with atrial fribrillation, as described in the below 
Study population section. After isolation, platelet aggregation was induced by collagen (Mascia Brunelli, 2 µg/mL).
Supernatants were stored at −80 °C for analysis of sNox2-dp, sCD40L, H2O2 and cAMP. Intra-assay and 
inter-assay coefficients of variation were 5.7% and 6.8%, respectively.
Measurement of C-reactive protein. The measurement of high-sensitivity C-reactive protein (CRP) was 
performed by the laboratory of D.E.A of Policlinico Umberto I – Sapienza University of Rome by using a neph-
elometric assay. The values were expressed as mg/dL.
Measurement of NT-proANP. Plasma NT-proANP levels were assessed with a commercially-available 
ELISA kit (Elabsciences) and expressed as pg/ml. Intra-assay and inter-assay coefficients of variation were < 10%.
Measurement of platelet sCD40L. Platelet levels of sCD40L were measured with the use of a commercial 
immunoassay (DRG International) and expressed as ng/ml. Intraassay and interassay coefficients of variation 
were 5% and 7% respectively.
Measurement of H2O2 production. Hydrogen peroxide (H2O2) was evaluated by a Colorimetric 
Detection Kit (Arbor Assays) and expressed as μmol/L. Intra-assay and inter-assay coefficients of variation were 
2.1% and 3.7% respectively.
Assay of platelet Soluble Nox2-derived Peptide. Extracellular levels of soluble Nox2-derived peptide 
(sNox2-dp), a marker of NADPH oxidase activation, were detected by ELISA as previously described15. The pep-
tide was recognized by the specific monoclonal antibody against the amino acidic sequence (224–268) of the extra 
membrane portion of Nox2 (catalytic core of NADPH oxidase), which is released in the medium upon platelet 
activation.
Values were expressed as pg/ml; intra-assay and inter-assay coefficients of variation were 5.2% and 6%, 
respectively.
Measurement of cAMP in platelets exposed to wild-type or mutant ANP. cAMP measurement 
was performed with the specific enzymeimmunoassay Biotrak (EIA) System (Amersham), following the manu-
facturer’s instructions.
Study population. We included 195 patients with non-valvular atrial fibrillation, who were treated with 
oral vitamin K antagonists (INR target 2.5), based on the CHA2DS2-VASc score34. The level of anticoagulation in 
these subjects was evaluated by the time in therapeutic range (TTR)35. Exclusion criteria were patients with pros-
thetic heart valves, severe valvulopathies, severe cognitive impairment, chronic infections, autoimmune systemic 
disease, active cancer and liver insufficiency (e.g. cirrhosis). At baseline, each patient provided written informed 
consent and patient’s anthropometric data and medical history were recorded. Baseline NT-proANP, platelet 
count and high-sensitivity C reactive protein were also measured. Cardiovascular risk factors, such as arterial 
hypertension, diabetes mellitus36 and heart failure37 were defined according to the currently used international 
definitions. The study protocol was approved by the local ethical board of Sapienza University of Rome and was 
conducted according to guidelines and regulations. Informed consent was obtained from all subjects.
Genetic analysis. For the analysis of C2238 ANP allele carrier status, genomic DNA was extracted from 
peripheral whole blood by a commercially available kit (QIAamp DNA Blood Mini Kit, Qiagen) and stored at 
−20 °C until genotyping.
Genotyping was carried out by using 50 ng of genomic DNA in a total volume of 20 µl containing 1 µl of pre-
formed Taqman assay 20X and 10 µl of Genotyping Master Mix 2X (Applied Biosystems, Foster City, CA). PCR 
reactions were carried out on a ViiA 7 PCR System (Applied Biosystems) at 95 °C for 10 min followed by 40 cycles 
of denaturation at 95 °C for 15 sec and annealing at 60 °C for 1 min. An electronic data file was generated, contain-
ing genotypes and the quality value.
Immunoblot analysis. NPR-C expression levels were measured in platelets isolated from 5 healthy subjects 
(3 males, 2 females, age 51.2 ± 12.4) and 5 patients with atrial fibrillation and history of cardiovascular diseases (3 
males, 2 females, age 57.8 ± 5.2). Platelet pellets were suspended in a 2X Lysis buffer (5 mM EDTA, 0.15 mol NaCl, 
0.1 mol Tris pH 8.0, 1% triton and 10 μg/ml of protease and phosphatase inhibitors cocktail). Equal amounts of 
protein (30 μg/lane) estimated by Bradford protein assay were solubilized in a 2X Leammli sample buffer con-
taining 20% of 2-mercaptoethanol. Proteins were separated by SDS-PAGE on a 10% polyacrylamide gel and 
then electro-transferred to nitrocellulose membranes. After protein transfer, the membranes were blocked in 1X 
TBST solution with 5% milk at room temperature for 1 h. After blocking, membranes were incubated with rabbit 
anti-NPR-C antibody (Santacruz) in 1X TBST with 5% BSA (1:500) overnight at 4 °C. Then, the membranes 
were incubated with a secondary antibody (Santa Cruz Biotechnology, 1:5000) and the immune complexes were 
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detected by enhanced chemiluminescence substrate. Densitometric analysis of the bands was performed by using 
Image J software.
Reagents. All materials were from Sigma Aldrich unless otherwise specified.
Transthoracic echocardiography (TTE). At baseline, each patient was examined by resting TTE; left 
atrium antero-posterior diameter (mm) and systolic left ventricular function as assessed by ejection fraction (EF 
%, Simpson method) were measured according to international guidelines38, 39.
Statistical analysis. Kolmogorov-Smirnov test was used to assess distribution of continuous variables, when 
appropriate. Continuous variables are expressed as mean ± SEM unless otherwise specified. Student t test or 
Mann-Whitney test was used to compare means or medians of two independent groups, when appropriate.
When more than two groups were compared one-way ANOVA test was used and Bonferroni post-hoc test 
was performed for intergroup comparisons. Categorical variables were compared by using the chi-squared test.
Statistical significance was set at a p value lower than <0.05. Analyses were performed with SPSS statistical 
software (SPSS Inc, Chicago, IL, version 20).
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